Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05489211 · ClinicalTrials.gov registry record · Phase 2
Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)
A Phase 2 study of Colorectal Cancer and Ovarian Cancer, sponsored by AstraZeneca.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 454
- Enrollment target
- 20
- Study locations
NCT05489211: Recruiting Phase 2 study of Colorectal Cancer and Ovarian Cancer, sponsored by AstraZeneca.
NCT05489211 is a Phase 2 study of Colorectal Cancer and Ovarian Cancer that is actively recruiting participants, run by AstraZeneca. The registered enrollment target is 454 participants, below the 1,543-participant average among 381 other Colorectal Cancer trials with a reported enrollment target (71% lower). The trial reports 20 study locations across 14 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05489211, a Phase 2 study of Colorectal Cancer and Ovarian Cancer, is actively recruiting participants, sponsored by AstraZeneca.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 454 participants
- Enrollment target
- 20
- Study locations
Study Summary
TROPION-PanTumor03 will investigate the safety, tolerability, and anti-tumour activity of Datopotamab Deruxtecan (Dato-DXd) as Monotherapy and in Combination with Anticancer Agents in Patients with Advanced/Metastatic Solid Tumours.
Primary Outcome
Proportion of participants who have a confirmed CR or confirmed PR, as determined by the investigator at local site per RECIST 1.1.
Conditions Studied
Interventions
- DRUG Carboplatin
- DRUG Capecitabine
- DRUG 5-Fluorouracil
- DRUG Volrustomig
- DRUG Datopotamab deruxtecan (Dato-DXd)
Study Locations (20)
California
- Research Site - Los Angeles
- Research Site - San Diego
- Research Site - Santa Rosa
Massachusetts
- Research Site - Boston
- Research Site - Boston
Ohio
- Research Site - Cincinnati
- Research Site - Columbus
Tennessee
- Research Site - Nashville
- Research Site - Nashville
Ontario
- Research Site - Toronto
- Research Site - Toronto
Indiana
- Research Site - Muncie
Kansas
- Research Site - Kansas City
Michigan
- Research Site - Grand Rapids
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 454 participants |
| Start Date | 2022-09-06 |
| Est. Completion | 2027-10-01 |
| Phase | Phase 2 |
What NCT05489211 shows while recruiting
NCT05489211 is an interventional study that assigns participants to a tested intervention. The registered 454 participants enrollment target is mid-sized for trials with a published cap, below the 1,543-participant average among 381 other Colorectal Cancer trials with a reported enrollment target (71% lower).
The record links to 7 conditions, with Colorectal Cancer appearing as the primary indexed condition, and to 5 interventions - of which Carboplatin is the first listed.
NCT05489211 names 20 study sites across 14 states, led by California, Massachusetts, Ohio.
Frequently Asked Questions
What is clinical trial NCT05489211 about?
NCT05489211 is a clinical study titled "Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)". TROPION-PanTumor03 will investigate the safety, tolerability, and anti-tumour activity of Datopotamab Deruxtecan (Dato-DXd) as Monotherapy and in Combination with Anticancer Agents in Patients with Advanced/Metastatic Solid Tumours.
What is the current status of trial NCT05489211?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 454 participants. The study started on 2022-09-06. Estimated completion is 2027-10-01.
What conditions does trial NCT05489211 study?
This clinical trial studies the following conditions: Colorectal Cancer, Ovarian Cancer, Endometrial Cancer, Gastric Cancer, Metastatic Castration-Resistant Prostate Cancer.
What interventions are being tested in trial NCT05489211?
The interventions under investigation include: Carboplatin (DRUG), Capecitabine (DRUG), 5-Fluorouracil (DRUG), Volrustomig (DRUG), Datopotamab deruxtecan (Dato-DXd) (DRUG).
Who is sponsoring clinical trial NCT05489211?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05489211 being conducted?
This trial has 20 study locations across California, Indiana, Kansas, Massachusetts, Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Colorectal Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05489211's enrollment target sits among peer trials
454 86th of 381 higher than 296 of 381 other Colorectal Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Colorectal Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Assess Adverse Events and Change in Disease Activity in Adult Participants Receiving Intravenously Infused Telisotuzumab Adizutecan Alone or With Standard of Care in Participants With Post Adjuvant Circulating Tumor DNA Positive Colorectal Cancer and No Radiographic Evidence of Disease
RECRUITING · Phase 2
-
A Study of Single Fraction Stereotactic Body Radiation Therapy (SBRT) Guided by Magnetic Resonance Imaging (MRI) in People With Liver Metastasis From Colorectal Cancer
RECRUITING · Phase 2
-
TAS-102 With or Without Celecoxib in ctDNA-defined Minimal Residual Disease in Colorectal Cancer After Completion of Adjuvant Chemotherapy
RECRUITING · Phase 2
-
A Phase 2 Trial of Fruquintinib and Tislelizumab in ctDNA-defined Minimal Residual Disease in Colorectal Cancer After Completion of Adjuvant Chemotherapy
RECRUITING · Phase 2
-
A Study of IBI363 in Subjects with Advanced Solid Malignancies
RECRUITING · Phase 2
-
Repurposing Riluzole for Cancer-Related Cognitive Impairment: A Pilot Trial
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05655936 · 454 participants · NA
Eliminating Severe Maternal Morbidity With Heart Health Doulas Trial
- NCT06510374 · 454 participants · Phase 3
Trial of Nadofaragene Firadenovec vs. Observation in Participants With Intermediate Risk Non-Muscle Invasive Bladder Cancer
- NCT06935357 · 454 participants · Phase 3
A Study to Learn About the Effects of Felzartamab Infusions on Adults With Immunoglobulin A Nephropathy (IgAN)
- NCT05541016 · 455 participants · Phase 2
De-Escalated Adjuvant and Definitive Radiation Therapy Informed by DART 2.0 ctHPV-DNA
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI